OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Modi on the Findings of DESTINY-Breast04 in HER2-Low Breast Cancer

June 6th 2022

Shanu Modi, MD, discusses the efficacy findings of the phase 3 DESTINY-Breast04 trial in patients with HER2-low metastatic breast cancer.

Dr. Westin on Subgroup Analysis of ZUMA-7 of Elderly Patients With R/R DLBCL

June 6th 2022

Jason R. Westin, MD, discusses subgroup analysis of elderly patients treated in the ZUMA-7 trial.

Dr. Ansell on the Updated Analysis of ECHELON-1 in Classical Hodgkin Lymphoma

June 5th 2022

Stephen M. Ansell, MD, PhD, discusses the updated analysis of the phase 3 ECHELON-1 in classical Hodgkin lymphoma.

Dr. Shah on the Survival Analysis of Older Patients With B-Cell ALL in the ZUMA-3 Trial

June 5th 2022

Bijal D. Shah, MD, MS, discusses the survival analysis of subgroups of patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated in the phase 3 ZUMA-3 trial.

Dr. Rampal on the Investigation of Navtemadlin in Relapsed/Refractory AML and MPNs

June 4th 2022

Raajit K. Rampal, MD, PhD, discusses the investigation of navtemadlin in relapsed/refractory acute myeloid leukemia and patients with blast phase myeloproliferative neoplasm in a phase 1b/2 trial.

Dr. Falchi on the Use of Epcoritamab with R-CHOP Therapy in High-Risk DLBCL

June 4th 2022

Lorenzo Falchi, MD, discusses the updated findings from the phase 1/2 EPCORE NHL-2 trial trial evaluating the subcutaneous administration of epcoritamab with R-CHOP in patients with high-risk diffuse large B-cell lymphoma.

Dr. Spira on the Potential Role of Adagrasib in NSCLC

June 4th 2022

Alexander I. Spira, MD, PhD, FACP, discusses the adagrasib in patients with non–small cell lung cancer in the phase 2 KRYSTAL-1 trial.

Dr. Wang on the Results of the Phase 3 SHINE Study in MCL

June 3rd 2022

Michael Wang, MD, discusses the results of the phase 3 SHINE trial in older patients with mantle cell lymphoma.

Dr. Ajani on the FDA Approvals of Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab in ESCC

June 2nd 2022

Jaffer A. Ajani, MD, discusses how the FDA approvals of first-line nivolumab plus chemotherapy and nivolumab plus ipilimumab in advanced or metastatic esophageal squamous cell carcinoma will improve treatment in this setting.

Dr. Vaishampayan on the Rationale of the PROBE Trial in RCC

June 1st 2022

Ulka Nitin Vaishampayan, MBBS, discusses the rationale of the phase 3 PROBE trial in advanced renal cell carcinoma.

Dr. Galsky on Initial Data From the CheckMate 274 Trial in Urothelial Cancer

June 1st 2022

Matthew Galsky, MD, discusses the design and findings of the phase 3 CheckMate 274 trial in urothelial cancer.

Dr. Cusnir on the Utilization of Y-90 Maintenance in CRC

June 1st 2022

Mike Cusnir, MD, discusses the utilization of SIR-Spheres® Y-90 resin microspheres as maintenance therapy in colorectal cancer.

Dr. Sallman on the Novel Menin Inhibitor KO-539 in AML

May 31st 2022

David Sallman, MD, discusses the background of the menin inhibitor, KO-539, in acute myeloid leukemia.

Dr. Yang on the Current Treatment Landscape in MCL

May 26th 2022

Jay Yang, MD, discusses the current treatment landscape of mantle cell lymphoma.

Dr. Tarantino on the Importance of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

May 26th 2022

Paolo Tarantino, MD, discusses the importance of the phase 3 DESTINY-Breast04 trial in HER2-low breast cancer.

Dr. Goel on the Need for Diverse Representation in Clinical Trials

May 26th 2022

Sanjay Goel, MD, MS, discusses the need for diverse representation in clinical trials.

Dr. Daneshmand on Emerging Treatments in Bladder Cancer

May 26th 2022

Sia Daneshmand MD, discusses emerging treatments in bladder cancer.

Dr. Liu on Enrolling Diverse Patients in the PREEMPT-CRC Trial in CRC

May 25th 2022

Julia Liu, MD, discusses enrolling diverse patients in the PREEMPT CRC trial in colorectal cancer.

Dr. Packiam the Investigation of Cabazitaxel Plus Gemcitabine with Pembrolizumab in Urothelial Carcinoma

May 25th 2022

Vignesh Packiam, MD, discusses the investigation of cabazitaxel and gemcitabine with pembrolizumab in patients who are unresponsive to docetaxel with non-muscle invasive urothelial carcinoma.

Dr. Raje on Unmet Needs with CAR T-Cell Therapy in Myeloma

May 25th 2022

Noopur Raje, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.